Recombinant Human CD37 Protein
Beta LifeScience
SKU/CAT #: BLK-02513P-100UG
Human CD37 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human CD37 Protein
Beta LifeScience
SKU/CAT #: BLK-02513P-100UG
Collections: Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human CD37 Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Ala113-Asn240. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P11049 |
Target Symbol | CD37 |
Synonyms | Tetraspanin-26; Tspan-26; CD37; CD37 molecule; GP52-40; MGC120234 |
Species | Human |
Expression System | HEK293 |
Tag | N-hFc |
Expression Range | Ala113-Asn240 |
Mol. Weight | The protein has a predicted MW of 41.9 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. |